Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-2066-2012Class II

VITROS 5,1 FS System Software For use in the in-vitro quantitative, semi quantitative, and qualitative...

Ortho-Clinical Diagnostics, Inc. / initiated 2012-05-21 / Terminated / root cause: software

Ortho-Clinical Diagnostics began a recall of VITROS 5,1 FS System Software For use in the in-vitro quantitative, semi quantitative, and qualitative measurement of variety of analytes of clinical interest on . FDA classified it as Class II and gives the reason as "software automatically switches the lot when a vancomycin (VANC) or valproic acid (VALP) reagent is depleted or the operator manually changes the lot in use causing lack of verification of proper quality assessment". As of , the recall status on record is Terminated, and MDM tags the root cause as software.

Recall record

Recall number
Z-2066-2012
Classification
Class II
Status
Terminated
Initiated
Posted
Terminated
Recalling firm
Ortho-Clinical Diagnostics, Inc.
Product
VITROS 5,1 FS System Software For use in the in-vitro quantitative, semi quantitative, and qualitative measurement of variety of analytes of clinical interest.
Product code
JJE Analyzer, Chemistry (Photometric, Discrete), For Clinical Use
Reason for recall
software automatically switches the lot when a vancomycin (VANC) or valproic acid (VALP) reagent is depleted or the operator manually changes the lot in use causing lack of verification of proper quality assessment.
Root cause tag
software
FDA root cause
Software design
Action
Ortho Clinical Diagnostics notified its foreign direct account consignees via email on May 21, 2012 and their direct account US consignees were sent an Urgent Distributor Safety Notice on May 22, 2012 via US Postal Service Priority Letter. The recall letter notified the consignees of the situation and that Ortho will replace their remaining inventory of non-expired GENs 14 or 15 for VITROS VALP Reagent only. Until then the consignees can continue using the VITROS VALP Reagent, GENs 14 or 15 until the replacement arrives. And to note that VITROS VANC Reagent, GENs 19 &20 are now expired. --- The letter also requested the consignees to complete and return the enclosed Confirmation of Receipt, no later than May 31, 2012. And to review the quality control beginning with the Calibration date of the VITROS VANC Reagent ( GEN 21 or above) or VITROS VALP (GEN & above) so that the QC results can be verified to be within acceptable ranges. --- For customers using VITROS VALP Reagent GEN 14 or 15, they were to respond as to the quantity of the non-expired GENs 14 and 15 remaining inventory; to load and use only one GEN of VITROS VALP Reagent at a time on the system until the replacement arrives. This notification letter should be posted by each VITROS System using the VITROS VALP Reagent or VITROS VANC Reagent or with the user documentation. And in addition, if these products were distributed then this information should be forwarded as well. For questions regarding this recall call 585-453-4110.
Quantity in commerce
2044
Distribution
Worldwide Distribution - USA (nationwide) and the countries of Australia, New Zealand, Brazil, Canada, Chile, Argentina, Paraquay, Ecuador, Colombia, India, Japan, Mexico, Panama, Singapore, Venezuela, UK, Northern Europe, France, Germany, Italy, Spain and Portugal.
Product codes and lots
Version 2.6.1 & Below

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-2066-2012
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-2066-2012Class IITerminatedVoluntary: Firm initiated
Z-2067-2012Class IITerminatedVoluntary: Firm initiated
Z-2068-2012Class IITerminatedVoluntary: Firm initiated